Blog

  • Scientists hack microbes to identify environmental sources of methane

    Scientists hack microbes to identify environmental sources of methane

    Roughly two-thirds of all emissions of atmospheric methane — a highly potent greenhouse gas that is warming planet Earth — come from microbes that live in oxygen-free environments like wetlands, rice fields, landfills and the guts of cows.

    Tracking atmospheric methane to its specific sources and quantifying their importance remains a challenge, however. Scientists are pretty good at tracing the sources of the main greenhouse gas, carbon dioxide, to focus on mitigating these emissions. But to trace methane’s origins, scientists often have to measure the isotopic composition of methane’s component atoms, carbon and hydrogen, to use as a fingerprint of various environmental sources.

    A new paper by researchers at the UC Berkeley, reveals how the activity of one of the main microbial enzymes involved in producing methane affects this isotope composition and complicates efforts to pinpoint environmental sources. The finding could change how scientists calculate the contributions of different environmental sources to Earth’s total methane budget and lead to a more accurate picture of where exactly atmospheric methane is coming from.

    “When we integrate all the sources and sinks of carbon dioxide into the atmosphere, we kind of get the number that we’re expecting from direct measurement in the atmosphere. But for methane, large uncertainties exist — within tens of percents for some sources — that challenge our ability to precisely quantify the relative importance and changes in time of the sources,” said UC Berkeley postdoctoral fellow Jonathan Gropp, who is first author of the paper. “To quantify the actual sources of methane, you need to really understand the isotopic processes involved in producing the methane.”

    Gropp teamed up with a molecular biologist and a geochemist at UC Berkeley to, for the first time, employ CRISPR to manipulate the activity of this key enzyme to reveal how methane-producing microbes — methanogens — interact with their food supply to produce methane.

    Jonathan Gropp inspecting microbial cultures of Methanosarcina acetivorans, the methane-producing microbe used in the new study. Oxygen is toxic to these microbes, so they are grown in air-tight glass tubes and handled inside an anaerobic glovebox, seen in background.

    Alienor Baskevitch/UC Berkeley

    “It is well understood that methane levels are rising, but there is a lot of disagreement on the underlying cause,” said co-author Dipti Nayak, UC Berkeley assistant professor of molecular and cell biology. “This study is the first time the disciplines of molecular biology and isotope biogeochemistry have been fused to provide better constraints on how the biology of methanogens controls the isotopic composition of methane.”

    Many elements have heavier or lighter versions, called isotopes, that are found in small proportions in nature. Humans are about 99% carbon-12 and 1% carbon-13, which is slightly heavier because it has an extra neutron in its nucleus. The hydrogen in water is 99.985% hydrogen-1 and 0.015% deuterium or hydrogen-2, which is twice as heavy because it has a neutron in its nucleus.

    The natural abundances of isotopes are reflected in all biologically produced molecules and variations can be used to study and fingerprint various biological metabolisms.

    “Over the last 70 years, people have shown that methane produced by different organisms and other processes can have distinctive isotopic fingerprints,” said geochemist and co-author Daniel Stolper, UC Berkeley associate professor of earth and planetary science. “Natural gas from oil deposits often looks one way. Methane made by the methanogens within cow guts looks another way. Methane made in deep sea sediments by microorganisms has a different fingerprint. Methanogens can consume or ‘eat,’ if you will, a variety of compounds including methanol, acetate or hydrogen; make methane; and generate energy from the process. Scientists have commonly assumed that the isotopic fingerprint depends on what the organisms are eating, which often varies from environment to environment, creating our ability to link isotopes to methane origins.”

    “I think what’s unique about the paper is, we learned that the isotopic composition of microbial methane isn’t just based on what methanogens eat,” Nayak said. “What you ‘eat’ matters, of course, but the amount of these substrates and the environmental conditions matter too, and perhaps more importantly, how microbes react to those changes.”

    “Microbes respond to the environment by manipulating their gene expression, and then the isotopic compositions change as well,” Gropp said. “This should cause us to think more carefully when we analyze data from the environment.”

    The paper was published Aug. 14 in the journal Science.

    Vinegar- and alcohol-eating microbes

    Methanogens — microorganisms that are archaea, which are on an entirely separate branch of the tree of life from bacteria — are essential to ridding the world of dead and decaying matter. They ingest simple molecules — molecular hydrogen, acetate or methanol, for example — excreted by other organisms and produce methane gas as waste. This natural methane can be observed in the pale Will-o’-the-wisps seen around swamps and marshes at night, but it’s also released invisibly in cow burps, bubbles up from rice paddies and natural wetlands and leaks out of landfills. While most of the methane in the natural gas we burn formed in association with hydrocarbon generation, some deposits were originally produced by methanogens eating buried organic matter.

    a wintry pond with weeds surrounded by grasses
    Wetlands are a major source of atmospheric methane. Methane-producing microbes, called methanogens, thrive in the bottom muck because it has low levels of oxygen, which is toxic to them.

    Robert Sanders/UC Berkeley

    The isotopic fingerprint of methane produced by methanogens growing on different “food” sources has been well established in laboratory studies, but scientists have found that in the complexity of the real world, methanogens don’t always produce methane with the same isotopic fingerprint as seen in the lab. For example, when grown in the lab, species of methanogens that eat acetate (essentially vinegar), methanol (the simplest alcohol), or molecular hydrogen (H2) produce methane, CH4, with a ratio of hydrogen and carbon isotopes different from the ratios observed in the environment.

    Gropp had earlier created a computer model of the metabolic network in methanogens to understand better how the isotope composition of methane is determined. When he got a fellowship to come to UC Berkeley, Stolper and Nayak proposed that he experimentally test his model. Stolper’s laboratory specializes in measuring isotope compositions to explore Earth’s history. Nayak studies methanogens and, as a postdoctoral fellow, found a way to use CRISPR gene editing in methanogens. Her group recently altered the expression of the key enzyme in methanogens that produces the methane — methyl-coenzyme M reductase (MCR) — so that its activity can be dialed down. Enzymes are proteins that catalyze chemical reactions.

    Experimenting with these CRISPR-edited microbes — in a common methanogen called Methanosarcina acetivorans growing on acetate and methanol — the researchers looked at how the isotopic composition of methane changed when the enzyme activity was reduced, mimicking what is thought to happen when the microbes are starved for their preferred food.

    They found that when MCR is at low concentrations, cells respond by altering the activity of many other enzymes in the cell, causing their inputs and outputs to accumulate and the rate of methane generation to slow so much that enzymes begin running both backwards and forwards. In reverse, these other enzymes remove a hydrogen from carbon atoms; running forward, they add a hydrogen. Together with MCR, they ultimately produce methane (CH4). Each forward and reverse cycle requires one of these enzymes to pull a hydrogen off of the carbon and add a new one ultimately sourced from water. As a result, the isotopic composition of methane’s four hydrogen molecules gradually comes to reflect that of the water, and not just their food source, which starts with three hydrogens.

    black and white image of round fluffy blobs arranged around a gossamer sheet of tissue
    Methanogens are archaea, a branch of the tree of life distinct from bacteria.

    Madison Williams/UC Berkeley

    This is different from typical assumptions for growth on acetate and methanol that assume no exchange between hydrogen derived from water and that from the food source.

    “This isotope exchange we found changes the fingerprint of methane generated by acetate and methanol consuming methanogens vs. that typically assumed. Given this, it might be that we have underestimated the contribution of the acetate-consuming microbes, and they might be even more dominant than we have thought,” Gropp said. “We’re proposing that we at least should consider the cellular response of methanogens to their environment when studying isotopic composition of methane.”

    Beyond this study, the CRISPR technique for tuning production of enzymes in methanogens could be used to manipulate and study isotope effects in other enzyme networks broadly, which could help researchers answer questions about geobiology and the Earth’s environment today and in the past.

    “This opens up a pathway where modern molecular biology is married with isotope-geochemistry to answer environmental problems,” Stolper said. “There are an enormous number of isotopic systems associated with biology and biochemistry that are studied in the environment; I hope we can start looking at them in the way molecular biologists now are looking at these problems in people and other organisms — by controlling gene expression and looking at how the stable isotopes respond.”

    For Nayak, the experiments are also a big step in discovering how to alter methanogens to derail production of methane and redirect their energy to producing useful products instead of an environmentally destructive gas.

    “By reducing the amount of this enzyme that makes methane and by putting in alternate pathways that the cell can use, we can essentially give them another release valve, if you will, to put those electrons, which they were otherwise putting in carbon to make methane, into something else that would be more useful,” she said.

    Other co-authors of the paper are Markus Bill of Lawrence Berkeley National Laboratory and former UC Berkeley postdoc Rebekah Stein, and Max Lloyd, who is a professor at Penn State University. Gropp was supported by a fellowship from the European Molecular Biology Organization. Nayak and Stolper were funded, in part, by Alfred B. Sloan Research Fellowships. Nayak also is an investigator with the Chan-Zuckerberg Biohub.

    RELATED INFORMATION

    Continue Reading

  • Google Ads adds ‘Share of Cost’ toggle to PMax reporting

    Google Ads adds ‘Share of Cost’ toggle to PMax reporting

    Google Ads is rolling out a new Cost Slider in Performance Max (PMax) campaign reporting, giving advertisers visibility into how much of their spend is going to each channel.

    Why we care. This toggle surfaces Share of Cost data – the percentage of total PMax spend each network or placement consumes – offering advertisers a clearer path to optimizing spend.

    How it works. Flip the Cost Slider on, and Google calculates and displays each channel’s share of total campaign spend.

    The feature was first spotted and shared by Thomas Eccel, head of Google Ads at JvM IMPACT, via LinkedIn.

    The upside. Eccel outlined three main benefits:

    1. Cost transparency: See exactly how budget is distributed across channels.
    2. Optimization insights: Compare spend share with conversion share to flag channels overspending without returns.
    3. Scaling opportunities: Spot underfunded, high-ROAS placements and push for incremental conversions.

    The big picture. When first introduced, PMax was criticized for its “black box” nature. This toggle update, and several other updates released this year, look to be working to quieten those assumptions. A simple toggle that breaks out channel-level spend could help advertisers make smarter, data-driven decisions.


    Search Engine Land is owned by Semrush. We remain committed to providing high-quality coverage of marketing topics. Unless otherwise noted, this page’s content was written by either an employee or a paid contractor of Semrush Inc.


    Anu AdegbolaAnu Adegbola

    Anu Adegbola has been Paid Media Editor of Search Engine Land since 2024. She covers paid search, paid social, retail media, video and more. In 2008, Anu’s career started with delivering digital marketing campaigns (mostly but not exclusively Paid Search) by building strategies, maximising ROI, automating repetitive processes and bringing efficiency from every part of marketing departments through inspiring leadership both on agency, client and marketing tech side. Outside editing Search Engine Land article she is the founder of PPC networking event – PPC Live and host of weekly podcast PPC Live The Podcast.
    She is also an international speaker with some of the stages she has presented on being SMX (US, UK, Munich, Berlin), Friends of Search (Amsterdam, NL), brightonSEO, The Marketing Meetup, HeroConf (PPC Hero), SearchLove, BiddableWorld, SESLondon, PPC Chat Live, AdWorld Experience (Bologna, IT) and more.

    Continue Reading

  • $59 Solo Buds, 26% Off on Amazon

    $59 Solo Buds, 26% Off on Amazon

    All products and services featured are independently chosen by editors. However, Billboard may receive a commission on orders placed through its retail links, and the retailer may receive certain auditable data for accounting purposes.

    Beats has long been a leader in the audio game, with their wireless headphones and earbuds consistently topping bestsellers lists and worn by some of the biggest celebrities and musicians in the industry.

    Explore

    See latest videos, charts and news

    But Beats products used to cost a pretty penny, running you into the hundreds of dollars for a brand new pair of buds. Fortunately, that’s no longer the case, as a new Amazon deal discounts the popular Beats Solo Buds down to an unheard-of $59.

    These earbuds used to be over $100 and were re-priced at $79.99 at the beginning of the year. Now you can an additional $20 off, making it the cheapest price we’ve ever seen for a pair of brand new Beats.

    Amazon

    AMAZON DEAL

    Beats Solo Buds Wireless Bluetooth Earbuds

    The Beats Solo Buds are wireless earbuds that boast the brand’s premium audio quality with big range, clarity and crispness. Music is loud and punchy and you can further customize your settings with the Beats App. These earbuds work with both Apple and Android devices.

    Battery life is super strong, with up to 18 hours with the included charging case. In a rush? A quick five-minute charge gets you up to one hour of playtime. The case itself is the smallest charging case Beats has ever made, and slides easily into your pockets or bag.

    The earbuds fit comfortably in your ears and this deal includes four different eartip sizes so you can find the best fit. We love how lightweight they feel and they’ve been great for workouts and runs too. Beats says its specially-designed “laser-cut vents” help to “improve audio performance while relieving pressure for added comfort.”

    Everything pairs easily over Bluetooth, with fewer drop outs, whether you’re listening to a playlist or taking a call.

    Regularly $79.99, get the Beats Studio Buds Wireless Earbuds on sale for just $59 on Amazon. The site says more than 4,000 shoppers have picked up these earbuds in the last few weeks alone, so we recommend adding to cart before the deal ends or quantities run out. Choose from four colors on sale. See full details here.

    Continue Reading

  • Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands | Pharmaceuticals industry

    Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands | Pharmaceuticals industry

    The price of the weight loss jab Mounjaro will rise by up to 170% in the UK, its US manufacturer has said, as Donald Trump ramps up pressure on drugmakers to increase their prices for Europeans so that they can make them more affordable for Americans.

    Eli Lilly has said it will increase the price of the drug from September, with a month’s supply of the highest dose rising from £122 to £330.

    Mounjaro contains tirzepatide and is self-administered in weekly injections.

    When it was launched in Britain in February 2024, Eli Lilly agreed to a list price “significantly below” its other European markets to stop delays in availability of the medicine through the NHS.

    The increase in the list price will align it “more consistently”, the company said, although it added that the NHS would not pay the new, higher price to ensure continued access for people with obesity and type 2 diabetes receiving it through the health service.

    Eli Lilly said it was working with private healthcare providers, which could negotiate their own confidential discounts with the company.

    Trump has threatened to use “every tool in our arsenal” to crack down on pharmaceutical companies charging higher prices in the US compared with other nations. The US pays about three times more for drugs compared with other developed countries, according to the Rand Corporation thinktank.

    On 31 July, Trump sent letters to 17 of the world’s biggest drugmakers, including Eli Lilly and Novo Nordisk, demanding cuts to drug prices for Americans within 60 days.

    “Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government and American patients,” Trump wrote. “But if you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.

    “Americans are demanding lower drug prices, and they need them today.”

    In May, Trump told reporters that a friend in London had told him he had bought the “fat shot drug” for $88, compared with $1,300 in New York.

    skip past newsletter promotion

    Pharmaceutical companies have cashed in on huge demand for weight loss treatments. Denmark’s Novo Nordisk has become one of the most prominent names in the field, launching Wegovy in the UK in September 2023, which turned it into one of the most valuable companies in Europe.

    While the jabs have increased profits at big drugmakers, they are racing to develop an equivalent pill, which would be a more convenient and cheaper alternative for patients and healthcare authorities.

    Eli Lilly said this month that a pill in early trial stages showed that participants on their highest dose lost an average of 12.4% of their body weight, compared with 0.9% of the control group.

    Novo Nordisk has submitted its oral weight loss drug for approval in the US. Its trial results showed that participants could lose about 15% of their body weight.

    Continue Reading

  • New high blood pressure guideline emphasizes prevention, early treatment to reduce CVD risk

    New high blood pressure guideline emphasizes prevention, early treatment to reduce CVD risk

    Guideline Highlights:

    • Nearly half of all adults in the U.S. have high blood pressure (≥130/80 mm Hg), which is the #1 preventable risk factor for cardiovascular disease, including heart attack, stroke and heart failure, as well as kidney disease, cognitive decline and dementia.
    • A new joint guideline from the American Heart Association and the American College of Cardiology advises earlier treatment that includes lifestyle modification and medications as appropriate, recommends close blood pressure management before, during and after pregnancy, and highlights using the new PREVENT™ risk calculator to estimate a person’s cardiovascular disease risk to tailor treatment.
    • The new guideline also reinforces the importance of healthy lifestyle behaviors, such as eating a nutritious diet, being physically active, and maintaining or achieving a healthy weight.
    • More recent research confirms that blood pressure affects brain health, including cognitive function and dementia, so early treatment is recommended for people diagnosed with high blood pressure to maintain brain health and cognition.
    • High blood pressure before, during and after pregnancy is important to monitor and treat quickly to reduce the risk of short- and long-term serious complications including preeclampsia.
    • The guideline, led by the American Heart Association and American College of Cardiology Joint Committee on Clinical Practice Guidelines, was developed in collaboration with and endorsed by 11 other health care organizations: the American Academy of Physician Associates; the American Association of Nurse Practitioners; the American College of Clinical Pharmacy; the American College of Preventive Medicine; the American Geriatrics Society; the American Medical Association; the American Society of Preventive Cardiology; the Association of Black Cardiologists; the National Medical Association; the Preventive Cardiovascular Nurses Association; and the Society of General Internal Medicine.

    Embargoed until 1:00 p.m. CT/2:00 p.m. ET Thursday, August 14, 2025

    DALLAS and WASHINGTON, August 14, 2025 — Preventing and managing high blood pressure with healthy lifestyle behaviors, such as following a heart-healthy diet including reducing salt intake, staying physically active, maintaining a healthy weight and managing stress—combined with early treatment with medication to lower blood pressure if necessary—are recommended to reduce the risk of heart attack, stroke, heart failure, kidney disease, cognitive decline and dementia, according to a new clinical guideline published today in the American Heart Association’s peer-reviewed journals Circulation and Hypertension, and in JACC, the flagship journal of the American College of Cardiology.

    The “2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults” replaces the 2017 guideline and includes new or updated recommendations for blood pressure management based on the latest scientific evidence to achieve the best health outcomes for patients.

    The new guideline reflects several major changes since 2017, including use of the American Heart Association’s PREVENTTM (Predicting Risk of cardiovascular disease EVENTs) risk calculator to estimate cardiovascular disease risk. It also provides updated guidance on medication options, including the early treatment for high blood pressure to reduce the risk of cognitive decline and dementia; use of specific medications including the possible addition of newer therapies such as GLP-1 medications for some patients with high blood pressure and overweight or obesity, and recommendations for managing high blood pressure before, during and after pregnancy.

    High blood pressure (including stage 1 or stage 2 hypertension) affects nearly half (46.7%) of all adults in the U.S., is the leading cause of death in the U.S. and around the world. The blood pressure criteria remain the same as the 2017 guideline:

    • normal blood pressure is less than 120/80 mm Hg;
    • elevated blood pressure is 120-129/80 mm Hg;
    • stage 1 hypertension is 130-139 mm Hg or 80-89 mm Hg; and
    • stage 2 hypertension is ≥140 mm Hg or ≥90 mm Hg. 

    “High blood pressure is the most common and most modifiable risk factor for heart disease,” said Chair of the guideline writing committee Daniel W. Jones, M.D., FAHA, dean and professor emeritus of the University of Mississippi School of Medicine in Jackson, Mississippi, and was a member of the writing committee for the 2017 high blood pressure guideline. “By addressing individual risks earlier and offering more tailored strategies across the lifespan, the 2025 guideline aims to aid clinicians in helping more people manage their blood pressure and reduce the toll of heart disease, kidney disease, Type 2 diabetes and dementia.”

    “This updated guideline is designed to support health care professionals—from primary care teams to specialists, and to all clinicians across health systems—with the diagnosis and care of people with high blood pressure. It also empowers patients with practical tools that can support their individual health needs as they manage their blood pressure, whether through lifestyle changes, medications or both,” Jones said.

    Importance of healthy lifestyle

    The new guideline reaffirms the critical role healthy lifestyle behaviors play in preventing and managing high blood pressure, and it encourages health care professionals to work with patients to set realistic, achievable goals. Healthy behaviors such as those in Life’s Essential 8, the American Heart Association’s metrics for heart health, remain the first line of care for all adults.

    Specific blood pressure-related guidance includes:

    • limiting sodium intake to less than 2,300 mg per day, moving toward an ideal limit of 1,500 mg per day by checking food labels (most adults in the U.S. get their sodium from eating packaged and restaurant foods, not the salt shaker);
    • ideally, consuming no alcohol or for those who choose to drink, consuming no more than two drinks per day for men and no more than one drink per day for women;
    • managing stress with exercise, as well as incorporating stress-reduction techniques like meditation, breathing control or yoga;
    • maintaining or achieving a healthy weight, with a goal of at least a 5% reduction in body weight in adults who have overweight or obesity;
    • following a heart healthy eating pattern, for example the DASH eating plan, which emphasizes reduced sodium intake and a diet high in vegetables, fruits, whole grains, legumes, nuts and seeds, and low-fat or nonfat dairy, and includes lean meats and poultry, fish and non-tropical oils;
    • increasing physical activity to at least 75-150 minutes each week including aerobic exercise (such as cardio) and/or resistance training (such as weight training); and
    • home blood pressure monitoring is recommended for patients to help confirm office diagnosis of high blood pressure and to monitor, track progress and tailor care as part of an integrated care plan.  

    Addressing each of these lifestyle factors is especially important for people with high blood pressure and other major risk factors for cardiovascular disease because it may prevent, delay or treat elevated or high blood pressure.

    New risk calculator and earlier intervention

    The new guideline recommends that health care professionals use the PREVENTTM risk calculator to estimate a person’s risk of a heart attack, stroke or heart failure. Developed by the American Heart Association in 2023, PREVENTTM is a tool to estimate 10- and 30-year risk of cardiovascular disease in people ages 30-79 years. It includes variables such as age, sex, blood pressure, cholesterol levels and other health indicators, including zip code as a proxy for social drivers of health. It is the first risk calculator that combines measures of cardiovascular, kidney and metabolic health to estimate risk for cardiovascular disease. More precise risk estimates can help guide treatment decisions personalized for each individual.

    In addition to the use of the PREVENTTM risk assessment tool, the new guideline recommends two important changes to laboratory testing for initial evaluation.

    • The ratio of urine albumin and creatinine (a test that assesses kidney health) is now recommended for all patients with high blood pressure. It was recommended as an optional test in the 2017 guideline.
    • The guideline also expands the indication for use of the plasma aldosterone-to-renin ratio test as a screening tool for primary aldosteronism in more patients including those with obstructive sleep apnea. (Primary aldosteronism is a condition that occurs when the adrenal glands make too much aldosterone, leading to high blood pressure and low potassium levels.)
    • Screening for primary aldosteronism may also be considered in adults with stage 2 hypertension to increase rates of detection, diagnosis and targeted treatment.

    Association of high blood pressure with cognitive decline and dementia

    While high blood pressure is a leading cause of heart attack and stroke, the new guideline highlights other serious risks. More recent research confirms that blood pressure affects brain health, including cognitive function and dementia. High blood pressure can damage small blood vessels in the brain, which is linked to memory problems and long-term cognitive decline. The guideline recommends early treatment for people diagnosed with high blood pressure with a goal of systolic blood pressure (top number) goal of <130 mm Hg for adults with high blood pressure to prevent cognitive impairment and dementia.

    Tailored approaches to medication for high blood pressure

    For many people with high blood pressure, especially those who have Type 2 diabetes, obesity or kidney disease, more than one medication may be needed to lower blood pressure to meet the <130/80 mm Hg criteria. The guideline highlights several types of blood pressure medications to initiate treatment, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), long-acting dihydropyridine calcium channel blockers and thiazide-type diuretics. If blood pressure remains high after one medication, clinicians may individualize treatment to either increase the dose or add a second medication from a different medication class.

    The guideline maintains the recommendation to begin treatment with two medications at once – preferably in a single combination pill – for people with blood pressure levels 140/90 mm Hg or higher (stage 2 hypertension). The guideline also suggests possible addition of newer therapies such as GLP-1 medications for some patients with high blood pressure and overweight or obesity.

    High blood pressure and pregnancy

    High blood pressure during pregnancy can have lasting effects on the mother’s health, including an increased risk of future high blood pressure and cardiovascular conditions. Without treatment, high blood pressure during pregnancy can lead to serious complications, such as preeclampsia, eclampsia, stroke, kidney problems and/or premature delivery. Women with high blood pressure who are planning a pregnancy or are pregnant should be counseled about the potential benefits of low-dose aspirin (81 mg/day) to reduce the risk of preeclampsia.

    For pregnant women with chronic hypertension (high blood pressure before pregnancy or diagnosed before 20 weeks of pregnancy), the new guideline recommends treatment with certain medications when systolic blood pressure reaches 140 mm Hg or higher and/or diastolic blood pressure reaches 90 mm Hg or higher. This change reflects growing evidence that tighter blood pressure control for some individuals during pregnancy may help to reduce the risk of serious complications.

    In addition, postpartum care is especially important because high blood pressure can begin or persist after delivery. The guideline urges continued blood pressure monitoring and timely treatment during the postpartum period to help prevent complications. Patients with a history of pregnancy-associated high blood pressure are encouraged to have their blood pressure measured at least annually.

    “It is important for people to be aware of the recommended blood pressure goals and understand how healthy lifestyle behaviors and appropriate medication use can help them achieve and maintain optimal blood pressure. Prevention, early detection and management of high blood pressure are critical to long-term heart and brain health, which means longer, healthier lives,” said Jones.

    This guideline was prepared by a volunteer writing committee on behalf of the American Heart Association and the American College of Cardiology Joint Committee on Clinical Practice Guidelines, and in collaboration with and endorsed by the American Academy of Physician Associates, the American Association of Nurse Practitioners, the American College of Clinical Pharmacy, the American College of Preventive Medicine, the American Geriatrics Society, the American Medical Association, the American Society of Preventive Cardiology, the Association of Black Cardiologists, the National Medical Association, the Preventive Cardiovascular Nurses Association and the Society of General Internal Medicine.

    Co-authors and members of the guideline writing committee include Co-Vice Chairs Keith C. Ferdinand, M.D., FAHA, FACC, and Sandra J. Taler, M.D., FAHA; Heather M. Johnson, M.D., M.S., FAHA, FACC; Daichi Shimbo, M.D.; Marwah Abdalla, M.D., M.P.H., FAHA, FACC; M. Martine Altieri, P.A.-C., M.H.Sc.; Nisha Bansal, M.D., M.A.S., FAHA; Natalie A. Bello, M.D., M.P.H., FACC; Adam P. Bress, Pharm.D., M.S.; Jocelyn Carter, M.D., M.P.H.; Jordana B. Cohen, M.D., M.S.C.E., FAHA; Karen J. Collins, M.B.A.; Yvonne Commodore-Mensah, Ph.D., M.H.S., B.S.N., R.N., FAHA; Leslie L. Davis, Ph.D., A.N.P.-B.C., FAHA, FACC; Brent Egan, M.D., FAHA; Sadiya S. Khan, M.D., M.Sc., FAHA, FACC; Donald M. Lloyd-Jones, M.D., Sc.M., FAHA, FACC; Bernadette Mazurek Melnyk, Ph.D., A.P.R.N.-C.N.P.; Eva A. Mistry, M.B.B.S., M.S.C.I., FAHA; Modele O. Ogunniyi, M.D., M.P.H., FAHA, FACC; Stacey L. Schott, M.D., M.P.H.; Sidney C. Smith Jr., M.D., FAHA; Amy W. Talbot, M.P.H.; Wanpen Vongpatanasin, M.D., FAHA, FACC; Karol E. Watson, M.D., Ph.D., FAHA, FACC; Paul K. Whelton, M.B., M.D., M.Sc., FAHA; and Jeff D. Williamson, M.D., M.H.S.

    The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.

    Additional Resources:

    • Available multimedia is on right column of release link.
    • News release translations in Spanish,Traditional Chinese (doc) and Chinese Simplified (doc) and Tagalog (doc) to be added as available. 
    • After August 14, 2025, view the manuscript online in Circulation, Hypertension and JACC.
    • American Heart Association health information: High Blood Pressure
    • American Heart Association Guideline Hub for Health Care Professionals (at embargo lift – Thursday, Aug. 14, at 2 p.m. ET)
    • 2025 High Blood Pressure Guideline Journal Hub (at embargo lift – Thursday, Aug. 14, at 2 p.m. ET)
    • JACC.org Guideline Hub (at embargo lift – Thursday, Aug. 14, at 2 p.m. ET)
    • 2025 High Blood Pressure Guideline-at-a-Glance (Available Aug. 15, at 2 p.m. ET)
    • CardioSmart.org High Blood Pressure Hub
    • Follow AHA/ASA news on X @HeartNews
    • Follow the ACC at @ACCinTouch
    • Follow news from the AHA’s flagship journal Circulation @CircAHA
    • Follow news from the AHA’s Hypertension journal @HyperAHA
    • Follow news from the ACC’s flagship journal JACC @JACCJournals

    ###

    About the American Heart Association

    The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.

    About the American College of Cardiology

    The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org or follow @ACCinTouch.

    For Media Inquiries: 214-706-1173

    American Heart Association: Michelle Kirkwood: Michelle.Kirkwood@heart.org and Amanda Ebert: Amanda.Ebert@heart.org

    American College of Cardiology: Olivia Walther: owalther@acc.org

    For Public Inquiries: 1-800-AHA-USA1 (242-8721)

    heart.org and stroke.org


    Continue Reading

  • Mayo Clinic identifies cellular ‘fountain of youth’ in aging immune systems

    Mayo Clinic identifies cellular ‘fountain of youth’ in aging immune systems

    The immune system is meant to protect the body from infection and disease. But with age, it can become less capable of doing so. However, Mayo Clinic researchers have found that some older people maintain “immune youth” – a new term coined by Mayo researchers to explain a young immune system in someone over age 60.

    We are studying why some individuals have a ‘fountain of youth’ in their immune systems. We want to learn from them.”


    Cornelia Weyand, M.D., Ph.D., Mayo Clinic rheumatologist and clinician-scientist

    She is a lead author on a perspective paper published in Nature Aging.

    Dr. Weyand’s research team discovered this cellular fountain of youth in more than 100 older patients who came to Mayo Clinic to receive treatment for an autoimmune disease that affects the arteries, including the aorta, called giant cell arteritis. Dr. Weyand and colleagues found in the diseased tissue of these patients specialized immune cells, called stem-like T cells. These immune cells behave like young stem cells that usually regenerate and aid healing and growth; but in this case, they were spreading the disease. This team of researchers also discovered autoimmune stem cells in humans previously.

    “We observed that these patients have very young immune systems despite being in their 60s and 70s. But the price they pay for that is autoimmunity,” she says.

    Autoimmunity is when the immune system mistakenly attacks healthy tissues and organs.

    In addition, the researchers saw that the immune checkpoint inhibitors that regulate the immune system were not working properly.

    Benefits of immune system aging

    “Contrary to what one may think, there are benefits to having an immune system that ages in tandem with the body,” says Jörg Goronzy, M.D., Ph.D., a Mayo Clinic researcher on aging who is a co-lead author of the paper. “We need to consider the price to pay for immune youthfulness. That price can be autoimmune disease.”

    Immune aging is a sophisticated adaptation mechanism that the immune system can use to prevent autoimmune disease, say the researchers.

    They are in the process of developing new diagnostic tests that will help find patients and healthy individuals who carry high numbers of immune stem cells and may be predisposed to autoimmune disease later in life. The research is part of a larger effort at Mayo Clinic called the Precure initiative, focused on developing tools that empower clinicians to predict and intercept biological processes before they evolve into disease or progress into complex, hard-to-treat conditions.

    Source:

    Journal reference:

    Weyand, C. M., & Goronzy, J. J. (2025) Sustained immune youth risks autoimmune disease in the aging host. Nature Aging. doi.org/10.1038/s43587-025-00919-w.

    Continue Reading

  • Coach parent Tapestry cuts profit forecast on tariff hit, shares slump – Reuters

    1. Coach parent Tapestry cuts profit forecast on tariff hit, shares slump  Reuters
    2. Tapestry shares plunge nearly 16% as Coach parent says tariffs will bite into profits  CNBC
    3. Tariffs, soft EPS outlook, Kate Spade weakness drive sharpest Tapestry selloff in 5 years  MSN
    4. Coach again drives growth for Tapestry in revenue, new customers  Yahoo Finance
    5. Tapestry (NYSE:TPR) Posts Better-Than-Expected Sales In Q2 But Stock Drops 16.3%  TradingView

    Continue Reading

  • Saudi wealth fund suffers $8bn writedown on ‘giga-projects’ – The Times

    Saudi wealth fund suffers $8bn writedown on ‘giga-projects’ – The Times

    1. Saudi wealth fund suffers $8bn writedown on ‘giga-projects’  The Times
    2. Saudi Arabia’s PIF makes $8bn writedown on value of flagship megaprojects  Financial Times
    3. Saudi Arabia’s sovereign wealth fund says AI embedded across every layer of organization  Business Recorder
    4. Saudi wealth fund’s assets jump, returns dip  Pensions & Investments
    5. PIF continued to drive the economic transformation of Saudi Arabia while shaping global economies in 2024, growing AuM by 19%  Public Investment Fund

    Continue Reading

  • Oil prices climb 2% to 1-week high as Fed rate cut, Trump-Putin talks loom – Reuters

    1. Oil prices climb 2% to 1-week high as Fed rate cut, Trump-Putin talks loom  Reuters
    2. Crude Oil Price Outlook – Crude Oil Continues to Struggle  FXEmpire
    3. WTI rises as geopolitical tensions ahead of US-Russia summit offset bearish fundamentals  Mitrade
    4. Crude Oil Rallies Ahead of Friday’s Trump-Putin Summit  Yahoo Finance
    5. Forecast update for crude oil -14-08-2025  Economies.com

    Continue Reading

  • Boyd Holbrook Joins Omar Sy in ‘Extraction’ TV Series at Netflix

    Boyd Holbrook Joins Omar Sy in ‘Extraction’ TV Series at Netflix

    Boyd Holbrook is the latest addition to the cast of the “” TV series currently in the works at Netflix, Variety has learned.

    The show was formally announced back in February with Omar Sy in the lead role. As reported at the time, it is set in the same world as Netflix’s “Extraction” films and has received an eight-episode order. Exact character details for Holbrook are being kept under wraps.

    The logline for the show states, “A mercenary (Sy) embarks on a dangerous mission to rescue hostages in Libya. Trapped between warring factions and ruthless killers, he must navigate life-or-death choices while confronting deep emotional wounds. The series explores the trauma, betrayal, and moral conflicts of characters pushed to the edge.”

    The casting keeps Holbrook in business with Netflix, as he has starred in the shows “The Sandman” and “Narcos” at the streamer. Holbrook is also known for his roles in films like “A Complete Unknown,” “The Bikeriders,” “Logan,” and “The Predator,” as well as shows like “Justified: City Primeval” and “Hatfields & McCoys.”

    He is repped by WME, Range Media Partners, Viewpoint and Yorn Levine Barnes.

    Glen Mazzara serves as writer, executive producer, and showrunner on the “Extraction” series. Anthony Russo, Joe Russo, Angela Russo-Otstot, Scott Nemes and Chris Castaldi executive produce for AGBO, with Sam Hargrave, Eric Gitter, and Peter Schwerin also executive producing. Ari Costa of AGBO will produce.

    The first “Extraction” film, which starred Chris Hemsworth, was released on Netflix in 2020. Hemsworth returned for the sequel in 2023. The films were based on the graphic novel “Ciudad” by Ande Parks. Joe Russo wrote the screenplay for both films and produced along with Anthony, Gitter, and Schwerin. Hargrave directed both films, with AGBO producing.

    Continue Reading